Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Key Highlights
- ➤RASONQUE U.S. launch generated $197.6 million in net product revenue in Q3
- ➤FDA approved RASONQUE for previously treated metastatic pancreatic adenocarcinoma on August 26, 2026
- ➤CHMP recommended EU marketing authorization for daraxonrasib in metastatic pancreatic cancer
- ➤Cash, cash equivalents and marketable securities totaled $3.7 billion at September 30, 2026
- ➤2026 GAAP operating expense guidance reiterated at $2.1 billion to $2.2 billion
Expert Statements
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union. We are focused on delivering RASONQUE with urgency and supporting patients as they begin treatment while we rapidly scale our global commercialization capabilities in preparation for potential international approvals. We also continue to advance our broad, integrated portfolio of RAS(ON) inhibitors across common, difficult-to-treat RAS-addicted cancers.”
* Received U.S. FDA approval and launched RASONQUE(®) (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy * Reported RASONQUE net product revenue of $198 million for the quarter, reflecting a partial quarter of sales following its U.S. commercial launch * Received positive CHMP opinion recommending marketing authorization of daraxonrasib in the European Union for metastatic pancreatic cancer * Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2026, and provided an update on corporate progress.
Get started
Create a free account to read the full story.